{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:00:10Z","timestamp":1788865210564,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.annonc.2023.12.011","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T11:57:04Z","timestamp":1703764624000},"page":"340-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma"],"prefix":"10.1016","volume":"35","author":[{"given":"N.","family":"Gavrielatou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fortis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Spathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Economopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.R.P.","family":"Foukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8388-5281","authenticated-orcid":false,"given":"I.M.","family":"Lelegiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rusakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vathiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.N.","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kastrinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kotsantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Vagia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Panayiotides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-4397","authenticated-orcid":false,"given":"D.L.","family":"Rimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Coukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Homicsko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Foukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Psyrri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2023.12.011_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2023.12.011_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Pri"},{"key":"10.1016\/j.annonc.2023.12.011_bib3","doi-asserted-by":"crossref","first-page":"vii252","DOI":"10.1093\/annonc\/mdq453","article-title":"Optimal treatment for recurrent\/metastatic head and neck cancer","volume":"21","author":"Vermorken","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2023.12.011_bib4","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.12.011_bib5","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2023.12.011_bib6","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.3390\/cancers12092691","article-title":"Immunotherapy breakthroughs in the treatment of recurrent or metastatic head and neck squamous cell carcinoma","volume":"12","author":"Borel","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.annonc.2023.12.011_bib7","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2023.12.011_bib8","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41379-020-00710-9","article-title":"Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer","volume":"34","author":"Emancipator","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annonc.2023.12.011_bib9","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study","volume":"35","author":"Bauml","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.12.011_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41416-018-0131-9","article-title":"Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012","volume":"119","author":"Mehra","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2023.12.011_bib11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2023.12.011_bib12","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.21.02198","article-title":"Pembrolizumab alone or with chemotherapy for recurrent\/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined positive score","volume":"40","author":"Burtness","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.12.011_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101977","article-title":"Biomarkers for immunotherapy response in head and neck cancer","volume":"84","author":"Gavrielatou","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annonc.2023.12.011_bib14","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/jamaoto.2019.2427","article-title":"Prognostic value of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma","volume":"145","author":"Spector","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.annonc.2023.12.011_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98811","article-title":"Frameshift events predict anti-PD-1\/L1 response in head and neck cancer","volume":"3","author":"Hanna","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.annonc.2023.12.011_bib16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2023.12.011_bib17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1158\/2767-9764.CRC-22-0299","article-title":"Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma","volume":"3","author":"Gavrielatou","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.annonc.2023.12.011_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/978-1-4939-9773-2_25","article-title":"High-plex spatially resolved RNA and protein detection using digital spatial profiling: a technology designed for immuno-oncology biomarker discovery and translational research","volume":"2055","author":"Beechem","year":"2020","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.annonc.2023.12.011_bib19","doi-asserted-by":"crossref","first-page":"btac757","DOI":"10.1093\/bioinformatics\/btac757","article-title":"GSEApy: a comprehensive package for performing gene set enrichment analysis in Python","volume":"39","author":"Fang","year":"2023","journal-title":"Bioinformatics"},{"key":"10.1016\/j.annonc.2023.12.011_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2023.12.011_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1860586","article-title":"A\u00a0gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma","volume":"10","author":"Budczies","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.annonc.2023.12.011_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37216-8","article-title":"Data mining on identifying diagnosis and prognosis biomarkers in head and neck squamous carcinoma","volume":"13","author":"Ju","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2023.12.011_bib23","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-19-3211","article-title":"B\u00a0cells improve overall survival in\u00a0HPV-associated squamous cell carcinomas and are activated by radiation and PD-1 blockade","volume":"26","author":"Kim","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2023.12.011_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-27237-0","article-title":"A\u00a0retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab","volume":"12","author":"Kuba","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2023.12.011_bib25","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.annonc.2023.12.011_bib26","article-title":"Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop","volume":"11","author":"Clifton","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2023.12.011_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2023.12.011_bib28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2023.12.011_bib29","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/hed.24406","article-title":"Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma","volume":"38","author":"Nguyen","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.annonc.2023.12.011_bib30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/bjc.2013.640","article-title":"Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer","volume":"110","author":"Balermpas","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2023.12.011_bib31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00262-016-1819-4","article-title":"Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors","volume":"65","author":"van Kempen","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.annonc.2023.12.011_bib32","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/bjc.2015.277","article-title":"Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma","volume":"113","author":"Oguejiofor","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2023.12.011_bib33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.29683","article-title":"CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG)","volume":"138","author":"Balermpas","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annonc.2023.12.011_bib34","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1186\/s12885-020-07234-0","article-title":"The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annonc.2023.12.011_bib35","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-18-1481","article-title":"Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer","volume":"24","author":"Wouters","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2023.12.011_bib36","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.3390\/cancers13215383","article-title":"The role of B cells in head and neck cancer","volume":"13","author":"Gavrielatou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2023.12.011_bib37","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B\u00a0cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2023.12.011_bib38","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B\u00a0cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2023.12.011_bib39","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.annonc.2023.12.011_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2023.100063","article-title":"Standardized pathology screening of mature tertiary lymphoid structures in cancers","volume":"103","author":"Vanhersecke","year":"2023","journal-title":"Lab Invest"},{"key":"10.1016\/j.annonc.2023.12.011_bib41","doi-asserted-by":"crossref","first-page":"899","DOI":"10.6004\/jnccn.2020.7590","article-title":"Evolving role of immunotherapy in recurrent metastatic head and neck cancer","volume":"18","author":"Le","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.annonc.2023.12.011_bib42","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.3389\/fimmu.2017.01830","article-title":"Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?","volume":"8","author":"Colbeck","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.annonc.2023.12.011_bib43","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/cmi.2017.35","article-title":"B\u00a0cell regulation in cancer and anti-tumor immunity","volume":"14","author":"Sarvaria","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.annonc.2023.12.011_bib44","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-16-0431","article-title":"The emerging role of B cells in tumor immunity","volume":"76","author":"Tsou","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2023.12.011_bib45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2023.12.011_bib46","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-020-2931-3","article-title":"Defining HPV-specific B cell responses in patients with head and neck cancer","volume":"597","author":"Wieland","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2023.12.011_bib47","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1038\/s41467-021-23355-x","article-title":"B\u00a0cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma","volume":"12","author":"Ruffin","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2023.12.011_bib48","article-title":"Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC","volume":"9","author":"Gui","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2023.12.011_bib49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2023.12.011_bib50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41523-021-00267-z","article-title":"Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection","volume":"7","author":"Glencer","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.annonc.2023.12.011_bib51","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1479-5876-9-204","article-title":"A\u00a0prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma","volume":"9","author":"Hamid","year":"2011","journal-title":"J\u00a0Transl Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423051189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423051189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T12:57:18Z","timestamp":1729083438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423051189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0923753423051189"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.12.011","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}